trending Market Intelligence /marketintelligence/en/news-insights/trending/irht498vzoyzvsuho6i10g2 content esgSubNav
In This List

Checkpoint Therapeutics plans common stock offering

Blog

A Pharmaceutical Company Capitalizes on M&A Activity with Brokerage Research

Blog

2021 Year in Review: Highlighting Key Investment Banking Trends

Blog

Insight Weekly: US stock performance; banks' M&A risk; COVID-19 vaccine makers' earnings

Blog

Global M&A By the Numbers: Q3 2021


Checkpoint Therapeutics plans common stock offering

Checkpoint Therapeutics Inc. is planning an underwritten public offering of its common stock.

The New York-based immuno-oncology biopharmaceutical company expects to grant the underwriters an overallotment option to buy up to an additional 15% of the shares offered.

Checkpoint plans to use the net proceeds for developing its product candidates, the potential in-license, acquisition, development and commercialization of other pharmaceutical products and for general corporate purposes.

National Securities Corp. is acting as sole book-running manager, while Lake Street Capital Markets LLC is acting as an independent underwriter for the offering.